|
FR2697752B1
(fr)
|
1992-11-10 |
1995-04-14 |
Rhone Poulenc Rorer Sa |
Compositions antitumorales contenant des dérivés du taxane.
|
|
US6214388B1
(en)
*
|
1994-11-09 |
2001-04-10 |
The Regents Of The University Of California |
Immunoliposomes that optimize internalization into target cells
|
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
US7371376B1
(en)
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
|
KR19990029749A
(ko)
*
|
1997-09-17 |
1999-04-26 |
미우라 아끼라 |
2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
|
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US6410328B1
(en)
*
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
EP0937456B1
(en)
*
|
1998-02-23 |
2004-07-21 |
Cilag AG International |
Erythropoietin liposomal dispersion
|
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
|
WO2000009071A2
(en)
*
|
1998-08-11 |
2000-02-24 |
All India Institute Of Medical Sciences |
A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
|
|
US20030049262A1
(en)
*
|
1998-10-02 |
2003-03-13 |
Susan Love |
Methods for identification, diagnosis, and treatment of breast cancer
|
|
WO2000020031A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Windy Hill Technology, Inc. |
Methods for identification, diagnosis, and treatment of breast cancer
|
|
WO2000054807A1
(en)
*
|
1999-03-17 |
2000-09-21 |
Mitsubishi Chemical Corporation |
Ligand-bonded complex
|
|
US6333348B1
(en)
*
|
1999-04-09 |
2001-12-25 |
Aventis Pharma S.A. |
Use of docetaxel for treating cancers
|
|
EP1645292A1
(en)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
|
AT500848B1
(de)
|
1999-06-25 |
2008-01-15 |
Genentech Inc |
Humanisierte anti-erbb2-antikörper
|
|
GB9915074D0
(en)
*
|
1999-06-28 |
1999-08-25 |
Cortecs Plc |
Ligand-binding composition
|
|
PL202369B1
(pl)
|
1999-08-27 |
2009-06-30 |
Genentech Inc |
Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
|
|
AU2136501A
(en)
*
|
1999-12-10 |
2001-06-18 |
Celator Technologies Inc. |
Lipid carrier compositions with protected surface reactive functions
|
|
US20040009229A1
(en)
*
|
2000-01-05 |
2004-01-15 |
Unger Evan Charles |
Stabilized nanoparticle formulations of camptotheca derivatives
|
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
EP1280923A2
(en)
*
|
2000-04-28 |
2003-02-05 |
Millennium Pharmaceuticals, Inc. |
14094, a human trypsin family member and uses thereof
|
|
CN1447696A
(zh)
|
2000-05-19 |
2003-10-08 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
|
AU6836301A
(en)
|
2000-06-20 |
2002-01-02 |
Idec Pharma Corp |
Treatment of b-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
|
DE60136490D1
(de)
*
|
2000-11-09 |
2008-12-18 |
Neopharm Inc |
Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
HUP0101480A2
(hu)
*
|
2001-04-11 |
2004-01-28 |
István Horváth |
Eljárás koleszterinből nyerhető baktérium-méretű partikulák előállítására
|
|
WO2002090510A2
(en)
*
|
2001-05-08 |
2002-11-14 |
Emory University |
Regulating immine responses using dendritic cells
|
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
|
WO2005010044A2
(en)
|
2003-07-08 |
2005-02-03 |
Genentech, Inc. |
Il-17 a/f heterologous polypeptides and therapeutic uses thereof
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
KR100576674B1
(ko)
|
2001-06-20 |
2006-05-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
|
ES2431929T3
(es)
|
2001-09-18 |
2013-11-28 |
Genentech, Inc. |
Composiciones y procedimientos para el diagnóstico y el tratamiento de tumores
|
|
EP2067472A1
(en)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
KR100965026B1
(ko)
|
2002-02-13 |
2010-06-21 |
이뮤놀로지 래보러토리스 인코포레이티드 |
미생물 감염증을 치료하기 위한 조성물 및 방법
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
KR100470535B1
(ko)
*
|
2002-06-27 |
2005-02-22 |
재단법인서울대학교산학협력재단 |
유피에이 항체 부착 이뮤노리포좀
|
|
HUP0600340A3
(en)
|
2002-07-15 |
2011-06-28 |
Genentech Inc |
Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
|
|
WO2004016750A2
(en)
|
2002-08-14 |
2004-02-26 |
Macrogenics, Inc. |
FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
|
WO2004035032A2
(en)
*
|
2002-08-20 |
2004-04-29 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
JP2006517917A
(ja)
*
|
2002-12-19 |
2006-08-03 |
アルザ・コーポレーシヨン |
血管新生性の組織増殖の治療方法
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
SI1613350T1
(sl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
WO2005037858A2
(en)
*
|
2003-10-16 |
2005-04-28 |
University Of Massachusetts |
Template-directed assembly of receptor signaling complexes
|
|
WO2005040163A1
(en)
|
2003-10-28 |
2005-05-06 |
Dr. Reddy's Laboratories Ltd |
Heterocyclic compounds that block the effects of advanced glycation end products (age)
|
|
US20050147664A1
(en)
*
|
2003-11-13 |
2005-07-07 |
Elan Pharma International Ltd. |
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
|
|
PL2295073T3
(pl)
|
2003-11-17 |
2014-09-30 |
Genentech Inc |
Przeciwciało przeciwko CD22 do leczenia nowotworu pochodzącego z układu krwiotwórczego
|
|
CA2555820C
(en)
|
2004-02-19 |
2016-01-19 |
Genentech, Inc. |
Cdr-repaired antibodies
|
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
|
CA2821167C
(en)
|
2004-05-03 |
2016-06-28 |
Merrimack Pharmaceuticals, Inc. |
Drug delivery liposomes containing anionic polyols or anionic sugars
|
|
EP1753455A2
(en)
|
2004-06-04 |
2007-02-21 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
|
JP4433918B2
(ja)
*
|
2004-07-15 |
2010-03-17 |
コニカミノルタエムジー株式会社 |
画像形成方法
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
MX2007001064A
(es)
|
2004-07-26 |
2007-04-12 |
Genentech Inc |
Metodos y composiciones para modular la activacion del factor de crecimiento de hepatocitos.
|
|
EP1809246B1
(en)
*
|
2004-10-08 |
2008-07-16 |
Alza Corporation |
Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
TW200618820A
(en)
*
|
2004-11-05 |
2006-06-16 |
Alza Corp |
Liposome formulations of boronic acid compounds
|
|
JP4990786B2
(ja)
*
|
2004-11-05 |
2012-08-01 |
イネックス ファーマシューティカルズ コーポレイション |
薬物リポソーム製剤を安定化するための組成物および方法
|
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
CN101437551A
(zh)
*
|
2004-11-19 |
2009-05-20 |
皇家飞利浦电子股份有限公司 |
用于分子成像的超声造影剂
|
|
ES2343746T3
(es)
|
2005-01-07 |
2010-08-09 |
Diadexus, Inc. |
Composiciones de anticuerpo ovr110 y metodos de uso.
|
|
ES2710439T3
(es)
|
2005-01-21 |
2019-04-25 |
Genentech Inc |
Dosificación fija de anticuerpos HER
|
|
BRPI0606557A2
(pt)
*
|
2005-02-09 |
2009-06-30 |
Genentech Inc |
método de inibição do abrigo de her2, método de redução do nìvel em soro de domìnio extracelular (ecd) de her2 em mamìferos, métodos de tratamento de cáncer em mamìferos, método de redução do nìvel de p95 her2 em célula e método de diagnóstico
|
|
KR101253576B1
(ko)
|
2005-02-23 |
2013-04-11 |
제넨테크, 인크. |
Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
|
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
EP1869076A2
(en)
|
2005-03-10 |
2007-12-26 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
|
EP1871424A2
(en)
*
|
2005-04-22 |
2008-01-02 |
Alza Corporation |
Immunoliposome composition for targeting to a her2 cell receptor
|
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
|
|
CA2610709A1
(en)
|
2005-06-06 |
2006-12-14 |
Genentech, Inc. |
Transgenic models for different genes and their use for gene characterization
|
|
US20070014845A1
(en)
*
|
2005-07-01 |
2007-01-18 |
Yuanpeng Zhang |
Liposomal delivery vehicle for hydrophobic drugs
|
|
EP2004695A2
(en)
|
2005-07-08 |
2008-12-24 |
Xencor, Inc. |
Optimized anti-ep-cam antibodies
|
|
US20070055199A1
(en)
*
|
2005-08-10 |
2007-03-08 |
Gilbert Scott J |
Drug delivery device for buccal and aural applications and other areas of the body difficult to access
|
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
ES2272178B1
(es)
*
|
2005-09-19 |
2008-03-16 |
Daniel Serrano Gil |
Una composicion para ser administrada a un mamifero o a un ser humano.
|
|
US20090155272A1
(en)
*
|
2005-09-30 |
2009-06-18 |
Muschler John L |
Targeted pharmaceuticals and ligands
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
US20070172520A1
(en)
*
|
2005-11-18 |
2007-07-26 |
University Of South Florida |
Immunotargeting of Nonionic Surfactant Vesicles
|
|
EP1962584A2
(en)
|
2005-11-21 |
2008-09-03 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
US20090186075A1
(en)
*
|
2005-12-22 |
2009-07-23 |
Roitt Ivan M |
Composition
|
|
AU2007233263A1
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
|
CN101437536A
(zh)
|
2006-03-23 |
2009-05-20 |
诺华有限公司 |
抗肿瘤细胞抗原抗体治疗
|
|
AU2007243946B2
(en)
|
2006-04-05 |
2012-11-29 |
Curis, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
|
EP2082645A1
(en)
|
2006-04-19 |
2009-07-29 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
|
JP2009537147A
(ja)
|
2006-05-15 |
2009-10-29 |
シー レーン バイオテクノロジーズ， エルエルシー |
インフルエンザウイルスに対する中和抗体
|
|
EP2023813A4
(en)
*
|
2006-05-15 |
2013-03-13 |
Dmitri B Kirpotin |
MAGNETIC MICROPARTICLES COMPRISING ORGANIC SUBSTANCES
|
|
AU2007281876B2
(en)
|
2006-06-26 |
2013-09-05 |
Macrogenics, Inc. |
FcgammaRIIB-specific antibodies and methods of use thereof
|
|
US8541190B2
(en)
*
|
2006-06-28 |
2013-09-24 |
Robert M. Weis |
Methods and materials for in vitro analysis and/or use of membrane-associated proteins, portions thereof or variants thereof
|
|
CA2657934C
(en)
|
2006-07-19 |
2017-04-04 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/p28 as a target for anti-inflammatory responses
|
|
WO2008013918A2
(en)
|
2006-07-26 |
2008-01-31 |
Myelin Repair Foundation, Inc. |
Cell cycle regulation and differentiation
|
|
JP5244103B2
(ja)
|
2006-08-09 |
2013-07-24 |
ホームステッド クリニカル コーポレイション |
器官特異的蛋白質およびその使用方法
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
US20100292090A1
(en)
|
2006-08-25 |
2010-11-18 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ｏｖｒ１１０抗体組成物および使用方法
|
|
CN101209243B
(zh)
*
|
2006-12-29 |
2010-12-08 |
石药集团中奇制药技术（石家庄）有限公司 |
一种脂质体药物及其制备方法
|
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
|
US8367052B2
(en)
|
2007-03-26 |
2013-02-05 |
General Regeneratives Holdings Inc. |
Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies
|
|
AU2008260498B2
(en)
|
2007-05-30 |
2012-11-29 |
Xencor, Inc. |
Methods and compositions for inhibiting CD32b expressing cells
|
|
CA2690334C
(en)
*
|
2007-06-08 |
2017-02-14 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
US9551033B2
(en)
*
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
|
ATE543835T1
(de)
|
2007-07-16 |
2012-02-15 |
Genentech Inc |
Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
|
|
ES2528922T3
(es)
|
2007-07-16 |
2015-02-13 |
Genentech, Inc. |
Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
|
|
WO2009020093A1
(ja)
*
|
2007-08-09 |
2009-02-12 |
Daiichi Sankyo Company, Limited |
デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム
|
|
SI2199390T1
(sl)
|
2007-08-30 |
2017-02-28 |
Daiichi Sankyo Company, Limited |
Proti-epha2 protitelo
|
|
AU2008345242B2
(en)
|
2007-10-31 |
2014-02-27 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
EP2220116B1
(en)
|
2007-11-12 |
2012-09-05 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
PT2247620T
(pt)
|
2008-01-31 |
2016-08-23 |
Genentech Inc |
Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
ES2542308T3
(es)
|
2008-03-10 |
2015-08-04 |
Theraclone Sciences, Inc. |
Composiciones y métodos para la terapia y diagnóstico de infecciones por citomegalovirus
|
|
EP2274334A2
(en)
|
2008-03-28 |
2011-01-19 |
Sea Lane Biotechnologies,llc. |
Neutralizing molecules to viral antigens
|
|
MX2010012368A
(es)
|
2008-05-16 |
2010-12-06 |
Genentech Inc |
Uso de biomarcadores para evaluar un tratamiento contra trastornos inflamatorios gastrointestinales con antagonistas de beta7-integrina.
|
|
ITMI20081052A1
(it)
*
|
2008-06-10 |
2009-12-11 |
Univ Milano Bicocca |
Liposomi in grado di legare efficacemente il peptide beta-amiloide
|
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
|
JP5642673B2
(ja)
|
2008-07-10 |
2014-12-17 |
セリナ・セラピユーテイツクス・インコーポレーテツド |
不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
JP5299922B2
(ja)
*
|
2009-02-04 |
2013-09-25 |
国立大学法人大阪大学 |
Ｈｂ−ｅｇｆ結合性タンパク質複合体
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
SG10201402742YA
(en)
|
2009-03-20 |
2014-08-28 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
CA2757382A1
(en)
|
2009-04-01 |
2010-10-21 |
Kristi Elkins |
Anti-fcrh5 antibodies and immunoconjugates
|
|
SG174891A1
(en)
|
2009-04-01 |
2011-11-28 |
Genentech Inc |
Treatment of insulin-resistant disorders
|
|
SG175305A1
(en)
|
2009-04-23 |
2011-11-28 |
Theraclone Sciences Inc |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
|
JP5705836B2
(ja)
|
2009-05-29 |
2015-04-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
|
|
CA2764729C
(en)
|
2009-06-26 |
2019-04-02 |
Sea Lane Biotechnologies, Llc |
Expression of surrogate light chains
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
|
EP2509997B1
(en)
|
2009-12-07 |
2017-08-30 |
i2 Pharmaceuticals, Inc. |
Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
|
|
WO2011076922A1
(en)
|
2009-12-23 |
2011-06-30 |
Synimmune Gmbh |
Anti-flt3 antibodies and methods of using the same
|
|
DK2519542T3
(en)
|
2009-12-28 |
2019-01-14 |
Onco Therapy Science Inc |
ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
|
|
US20130202625A1
(en)
*
|
2010-01-21 |
2013-08-08 |
The Regents Of The University Of Californa |
Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
|
|
WO2011089211A1
(en)
|
2010-01-22 |
2011-07-28 |
Synimmune Gmbh |
Anti-cd133 antibodies and methods of using the same
|
|
KR20130000384A
(ko)
|
2010-02-18 |
2013-01-02 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
뉴레귤린 길항제 및 암의 치료에서의 그의 용도
|
|
NZ601293A
(en)
|
2010-02-23 |
2014-10-31 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor
|
|
JP2013528357A
(ja)
|
2010-03-29 |
2013-07-11 |
ザイムワークス，インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
|
CN102958941A
(zh)
|
2010-05-03 |
2013-03-06 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
|
CA2798273A1
(en)
|
2010-05-04 |
2011-11-10 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
WO2012021786A2
(en)
|
2010-08-12 |
2012-02-16 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
|
EP3556396B1
(en)
|
2010-08-31 |
2022-04-20 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
|
WO2012030842A2
(en)
|
2010-09-03 |
2012-03-08 |
Academia Sinica |
Anti-c-met antibody and methods of use thereof
|
|
US20120201821A1
(en)
|
2010-10-25 |
2012-08-09 |
Gonzalez Jr Lino |
Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
|
|
EP2640831A1
(en)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
|
WO2012078695A2
(en)
|
2010-12-06 |
2012-06-14 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
|
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
|
EP2675478A4
(en)
|
2011-02-14 |
2015-06-10 |
Theraclone Sciences Inc |
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
|
|
WO2012112730A2
(en)
|
2011-02-15 |
2012-08-23 |
Merrimack Pharmaceuticals, Inc. |
Compositions and methods for delivering nucleic acid to a cell
|
|
AU2012229188A1
(en)
|
2011-03-15 |
2013-09-26 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
|
KR20130137688A
(ko)
|
2011-03-31 |
2013-12-17 |
제넨테크, 인크. |
베타7 인테그린 길항제를 투여하는 방법
|
|
KR101589135B1
(ko)
|
2011-04-20 |
2016-01-29 |
주식회사 셀앤바이오 |
인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
WO2013003647A2
(en)
|
2011-06-28 |
2013-01-03 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
WO2013033069A1
(en)
|
2011-08-30 |
2013-03-07 |
Theraclone Sciences, Inc. |
Human rhinovirus (hrv) antibodies
|
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
|
PH12014500925A1
(en)
|
2011-10-28 |
2014-06-09 |
Genentech Inc |
Therapeutic combinations and methods of treating melanoma
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
AU2012346540C1
(en)
|
2011-11-30 |
2019-07-04 |
Genentech, Inc. |
ErbB3 mutations in cancer
|
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
|
US9493532B2
(en)
|
2011-12-15 |
2016-11-15 |
The University Of Chicago |
Compositions for cancer therapy using mutant light molecules with increased affinity to receptors
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
KR102161271B1
(ko)
*
|
2012-02-17 |
2020-09-29 |
셀젼 코퍼레이션 |
감열성 나노입자 제제 및 그의 제조 방법
|
|
ES2680151T3
(es)
|
2012-03-01 |
2018-09-04 |
Amgen Research (Munich) Gmbh |
Moléculas de unión de polipéptidos de larga duración
|
|
NZ630990A
(en)
|
2012-03-16 |
2016-04-29 |
Merck Patent Gmbh |
Aminoacid lipids
|
|
NZ631034A
(en)
|
2012-03-16 |
2016-06-24 |
Merck Patent Gmbh |
Targeting aminoacid lipids
|
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
|
CN104334724B
(zh)
|
2012-04-09 |
2020-09-01 |
第一三共株式会社 |
抗-fgfr2抗体
|
|
KR20190020838A
(ko)
|
2012-04-27 |
2019-03-04 |
다이이찌 산쿄 가부시키가이샤 |
항-robo4 항체
|
|
US9717724B2
(en)
|
2012-06-13 |
2017-08-01 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
US20150210758A1
(en)
|
2012-08-14 |
2015-07-30 |
Nanyang Technological University |
Angiopoietin-like 4 antibody and a method of its use in cancer treatment
|
|
KR101850591B1
(ko)
|
2012-10-05 |
2018-04-19 |
제넨테크, 인크. |
염증성 장 질환의 진단 및 치료 방법
|
|
KR102310697B1
(ko)
|
2012-11-20 |
2021-10-12 |
스펙트럼 파마슈티컬즈 인크 |
치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
|
|
JP6998646B2
(ja)
|
2012-11-30 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
|
|
EP2925361A4
(en)
|
2012-12-03 |
2016-06-29 |
Merrimack Pharmaceuticals Inc |
COMBINATION THERAPY FOR THE TREATMENT OF HER2-POSITIVE CARCINOMA
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
|
EP2970449B1
(en)
|
2013-03-15 |
2019-09-25 |
Amgen Research (Munich) GmbH |
Single chain binding molecules comprising n-terminal abp
|
|
US11156608B2
(en)
|
2013-03-15 |
2021-10-26 |
The Trustees Of The University Of Pennsylvania |
Method for the site-specific covalent cross-linking of antibodies to surfaces
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
|
AU2014241552B2
(en)
|
2013-03-27 |
2018-08-16 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
|
MX376808B
(es)
|
2013-05-24 |
2025-03-07 |
Medimmune Llc |
Anticuerpos anti-b7-h5 y sus usos.
|
|
BR112015029754A2
(pt)
|
2013-05-31 |
2017-09-26 |
Genentech Inc |
anticorpos anti-teicoico da parede e conjugados
|
|
MA38686A1
(fr)
|
2013-05-31 |
2017-10-31 |
Genentech Inc |
Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
|
|
CR20160132A
(es)
|
2013-08-12 |
2016-08-25 |
Genentech Inc |
Composiciones y método para tratar condiciones asociadas con el complemento
|
|
TWI688401B
(zh)
|
2013-09-13 |
2020-03-21 |
美商安進公司 |
用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
|
|
US9931401B2
(en)
|
2013-10-08 |
2018-04-03 |
Daiichi Sankyo Company, Limited |
Combination comprising anti-fibroblast growth factor receptor 2 (FGFR2) antibody and a tyrosine kinase inhibitor
|
|
MA39804A
(fr)
|
2014-03-27 |
2017-02-01 |
Hoffmann La Roche |
Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
|
|
UY36245A
(es)
|
2014-07-31 |
2016-01-29 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
JP6749312B2
(ja)
|
2014-07-31 |
2020-09-02 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ |
最適化された種間特異的二重特異性単鎖抗体コンストラクト
|
|
WO2016022723A1
(en)
|
2014-08-05 |
2016-02-11 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
|
|
JP6751393B2
(ja)
|
2014-12-03 |
2020-09-02 |
ジェネンテック， インコーポレイテッド |
抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用
|
|
KR20170086536A
(ko)
|
2014-12-03 |
2017-07-26 |
제넨테크, 인크. |
항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
|
|
WO2016123329A2
(en)
|
2015-01-28 |
2016-08-04 |
Genentech, Inc. |
Gene expression markers and treatment of multiple sclerosis
|
|
EP3259597B2
(en)
|
2015-02-19 |
2026-04-15 |
Compugen Ltd. |
Pvrig polypeptides and methods of treatment
|
|
SG11201706583PA
(en)
|
2015-02-19 |
2017-09-28 |
Compugen Ltd |
Anti-pvrig antibodies and methods of use
|
|
EP3978530A1
(en)
|
2015-02-26 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Integrin beta7 antagonists and methods of treating crohn's disease
|
|
DK3283524T3
(da)
|
2015-04-17 |
2023-05-30 |
Amgen Res Munich Gmbh |
BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3
|
|
AU2016260306B2
(en)
|
2015-05-12 |
2022-10-06 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for making antibody conjugates
|
|
US11318131B2
(en)
|
2015-05-18 |
2022-05-03 |
Ipsen Biopharm Ltd. |
Nanoliposomal irinotecan for use in treating small cell lung cancer
|
|
ES2810700T3
(es)
|
2015-05-29 |
2021-03-09 |
Hoffmann La Roche |
Metilación del promotor de PD-L1 en cáncer
|
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
PL3337467T3
(pl)
|
2015-08-20 |
2021-06-14 |
Ipsen Biopharm Ltd. |
Terapia skojarzona z zastosowaniem liposomalnego irynotekanu i inhibitora parp do leczenia nowotworu
|
|
PL3337478T5
(pl)
|
2015-08-21 |
2026-05-04 |
Ipsen Biopharm Ltd. |
Kombinacja leków obejmująca liposomalny irynotekan, oksaliplatynę, 5-fluorouracyl i leukoworynę do leczenia nowotworu trzustki z przerzutami
|
|
IL324412A
(en)
|
2015-10-06 |
2026-01-01 |
Genentech Inc |
A method for treating multiple sclerosis
|
|
AU2016340153B2
(en)
|
2015-10-16 |
2022-06-02 |
Ipsen Biopharm Ltd. |
Stabilizing camptothecin pharmaceutical compositions
|
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
|
EP3383908A1
(en)
|
2015-12-02 |
2018-10-10 |
Stsciences, Inc. |
Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
|
|
MX2018006613A
(es)
|
2015-12-02 |
2019-01-30 |
Stcube & Co Inc |
Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
|
|
JOP20170017B1
(ar)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
|
|
SG11201805770UA
(en)
|
2016-02-03 |
2018-08-30 |
Amgen Res Munich Gmbh |
BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
|
|
CA3011942A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
|
PL3468997T3
(pl)
|
2016-06-08 |
2024-12-16 |
Xencor, Inc. |
Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
|
|
US20200148750A1
(en)
|
2016-07-21 |
2020-05-14 |
Emory University |
Ebola Virus Antibodies and Binding Agents Derived Therefrom
|
|
SG11201901077RA
(en)
|
2016-08-17 |
2019-03-28 |
Compugen Ltd |
Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
|
|
EP4372002A3
(en)
|
2016-09-14 |
2024-08-14 |
The Trustees Of The University Of Pennsylvania |
Proximity-based sortase-mediated protein purification and ligation
|
|
US20190300607A1
(en)
|
2016-10-12 |
2019-10-03 |
Daiichi Sankyo Company, Limited |
Composition containing anti-robo4 antibody and other agents
|
|
EP3535026A1
(en)
|
2016-11-02 |
2019-09-11 |
Ipsen Biopharm Limited |
Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
|
|
ES3039621T3
(en)
|
2016-12-22 |
2025-10-23 |
Daiichi Sankyo Co Ltd |
Anti-cd3 antibody, and molecule containing said antibody
|
|
AU2018214223B2
(en)
|
2017-02-02 |
2025-08-14 |
Amgen Inc. |
Low pH pharmaceutical composition comprising T cell engaging antibody constructs
|
|
RU2019128134A
(ru)
|
2017-02-07 |
2021-03-09 |
Дайити Санкио Компани, Лимитед |
Антитело против gprc5d и молекула, содержащая антитело
|
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
TWI782000B
(zh)
|
2017-03-30 |
2022-11-01 |
日商第一三共股份有限公司 |
抗ｇｐｒ２０抗體、其製造方法及其應用
|
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
|
KR102700015B1
(ko)
|
2017-05-05 |
2024-08-29 |
암젠 인크 |
개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
|
|
EP3630830A1
(en)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
|
KR20250036941A
(ko)
|
2017-05-31 |
2025-03-14 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
|
WO2018222685A1
(en)
|
2017-05-31 |
2018-12-06 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
|
EP3635007A1
(en)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands
|
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
|
TW201927336A
(zh)
|
2017-10-05 |
2019-07-16 |
日商第一三共股份有限公司 |
細胞毒性ｔ細胞耗竭用組成物
|
|
TWI827570B
(zh)
|
2017-12-11 |
2024-01-01 |
美商安進公司 |
雙特異性抗體產品之連續製造製程
|
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
|
US20210115156A1
(en)
|
2018-04-13 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fc-engineered anti-human ige antibodies and methods of use
|
|
US12084489B2
(en)
|
2018-05-02 |
2024-09-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
|
|
CN112533946A
(zh)
*
|
2018-05-15 |
2021-03-19 |
旗舰创业创新六公司 |
病原体防治组合物及其用途
|
|
AR117650A1
(es)
|
2018-10-11 |
2021-08-18 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecíficos
|
|
CA3119037A1
(en)
|
2018-12-11 |
2020-06-18 |
Disruption Labs Inc. |
Compositions for the delivery of therapeutic agents and methods of use and making thereof
|
|
AU2020290573B2
(en)
|
2019-06-13 |
2026-01-29 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
CN114729045B
(zh)
|
2019-09-26 |
2025-09-09 |
斯特库比公司 |
对糖基化的ctla-4特异性的抗体及其使用方法
|
|
CN114829404B
(zh)
|
2019-10-09 |
2025-09-09 |
斯特库比公司 |
对糖基化的lag3特异的抗体及其使用方法
|
|
CA3156683A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
MX2022011632A
(es)
|
2020-03-19 |
2022-10-13 |
Amgen Inc |
Anticuerpos contra mucina 17 y usos de los mismos.
|
|
MX2023003997A
(es)
|
2020-10-06 |
2023-06-15 |
Xencor Inc |
Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les).
|
|
CA3200317A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
AU2022248779A1
(en)
|
2021-03-29 |
2023-09-28 |
Daiichi Sankyo Company, Limited |
Stable multispecific molecule and use thereof
|
|
WO2022234102A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
|
WO2023054243A1
(ja)
*
|
2021-09-30 |
2023-04-06 |
日油株式会社 |
細胞指向性を有する脂質ナノ粒子
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|
|
CN121293357A
(zh)
|
2022-08-22 |
2026-01-09 |
雅博得乐医疗公司 |
Dll3结合分子及其用途
|
|
JP2025533434A
(ja)
|
2022-09-14 |
2025-10-07 |
アムジエン・インコーポレーテツド |
二重特異性分子安定化組成物
|
|
MX2025014635A
(es)
|
2023-06-14 |
2026-02-03 |
Amgen Inc |
Moleculas captadoras de enmascaramiento de celulas t
|
|
NL2038054B1
(en)
|
2024-06-25 |
2026-01-15 |
Academisch Ziekenhuis Leiden |
A method for preparing liposomes
|